Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders. Complaints experienced by patients suffering from IBS and its co-morbidities strongly impair quality of life, and available treatments are often unsatisfactory. Cannabidiol (CBD) is a natural compound of the cannabis plant that is gaining popularity as a remedy for various health issues.
Researchers suggest that CBD shows promise in treating pain and inflammation, thus managing the main symptoms of irritable bowel syndrome (IBS). Although studies are still in the early stages, CBD is increasingly used as an alternative treatment for the well-being of the patients.
There is no established or recommended dose for CBD in managing IBS. FDA does not currently approve any CBD products for IBS. As a result, dosages are actively open to interpretation, and patients should treat them with caution.
As FDA does not currently regulate products, choose CBD products that:
- contain no more than 0.3% THC, per Agriculture Improvement Act
- have a proof of third-party testing by an accredited lab
- passed tests for pesticides, heavy metals etc.
- passed product potency evaluations and safety testing
- are from a company that provides certificates of analysis for all their products
CBD products show some promise in alleviating IBS symptoms such as pain and inflammation. However, to date, no product containing CBD has FDA approval to treat the condition or its symptoms.